A Bertolotto

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

P. Gallo, A. Bertolotto, P. Perini, 2001, European cytokine network.

Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years.

M Rovaris, M Filippi, B Benedetti, 2006, Brain : a journal of neurology.

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory

P. Carrieri, G. Orefice, A. Bertolotto, 2002, Journal of neurology, neurosurgery, and psychiatry.

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.

R. Mutani, A. Bertolotto, A Bertolotto, 2000, Immunopharmacology.

I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

R. Zivadinov, D. Cookfair, A. Bertolotto, 2007, Multiple sclerosis.